Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2008:781–801. doi: 10.1007/978-3-540-73277-8_9

Hematological and Oncological Emergencies

Hartmut Bertz 3, Hartmut Henß 4, Beate Lubrich 5
Editors: Dietmar P Berger1, Monika Engelhardt1, Hartmut Henß2, Roland Mertelsmann1
PMCID: PMC7120105

The content is available as a PDF (266.8 KB).

References

  • 1.Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42:2433–53. doi: 10.1016/j.ejca.2006.05.002. [DOI] [PubMed] [Google Scholar]
  • 2.Bertz H, Auner HW, Weissinger F, et al. Antimicrobial therapy of febrile complications after high-dose chemo-/radiotherapy and autologous hematopoietic stem cell transplantation: guidelines of the AGIHO/DGHO. Ann Hematol. 2003;82(suppl 2):S167–74. doi: 10.1007/s00277-003-0771-5. [DOI] [PubMed] [Google Scholar]
  • 3.Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences and new directions for its management. Cancer. 2004;100:228–37. doi: 10.1002/cncr.11882. [DOI] [PubMed] [Google Scholar]
  • 4.Guidelines Working Group ESMO. Hematopoietic growth factors: ESMO Recommendations for the application. Ann Oncol. 2007;18(Suppl.2):ii89–91. doi: 10.1093/annonc/mdm052. [DOI] [PubMed] [Google Scholar]
  • 5.Penack O, Beinert T, Buchheidt D, et al. Management of sepsis in neutropenia: guidelines of the AGIHO/DGHO. Ann Hematol. 2006;85:424–33. doi: 10.1007/s00277-006-0096-2. [DOI] [PubMed] [Google Scholar]
  • 6.Sipsas NV, Bodey GP, Kostoyiannis DP. Perspectives for the management of febrile neutropenic patients. Cancer. 2005;103:1103–13. doi: 10.1002/cncr.20890. [DOI] [PubMed] [Google Scholar]
  • 7.Smith TJ, Khatcheressian J, Lyman GJ, et al. 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–205. doi: 10.1200/JCO.2006.06.4451. [DOI] [PubMed] [Google Scholar]
  • 1.http://www.nccn.org/professionals/physician_gls/pdf/fever.pdf NCCN
  • 1.Aurora R, Milite F, Vander Els NJ. Respiratory emergencies. Semin Oncol. 2000;27:256–69. [PubMed] [Google Scholar]
  • 2.Kanani RS, Drachmann DE. Malignant obstruction of the superior vena cava. N Engl J Med. 2006;354:e7. doi: 10.1056/NEJMicm050661. [DOI] [PubMed] [Google Scholar]
  • 3.Rowell NP, Gleeson FV. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus. Cochrane Database Syst Rev 2001;CD001316 [DOI] [PubMed]
  • 4.Wilson LD, Detterbeck FC, Yahalom J. Superior vena cava syndrome with malignant causes. N Engl J Med. 2007;356:1862–9. doi: 10.1056/NEJMcp067190. [DOI] [PubMed] [Google Scholar]
  • 1.http://www.emedicine.com/emerg/topic561.htm E-medicine
  • 2.http://www.cancer.gov/cancertopics/pdq/supportivecare/
cardiopulmonary/patient NCI Cancer Topics
  • 3.http://www.fpnotebook.com/CV303.htm Family Practice
  • 1.Bagley CA, Gokaslan ZL. Cauda equina syndrome caused by primary and metastatic neoplasms. Neurosurg Focus. 2004;16:e3. doi: 10.3171/foc.2004.16.6.3. [DOI] [PubMed] [Google Scholar]
  • 2.Byrne T. Spinal cord compression from epidural metastases. N Engl J Med. 1992;327:614–7. doi: 10.1056/NEJM199208273270907. [DOI] [PubMed] [Google Scholar]
  • 3.Loblaw DA, Laperriere NJ. Emergency treatment of malignant extradural spinal cord compression: an evidence based guideline. J Clin Oncol. 1998;16:1613–24. doi: 10.1200/JCO.1998.16.4.1613. [DOI] [PubMed] [Google Scholar]
  • 4.Maranzano E, Bellavita R, Rossi R, et al. Short-course versus split-course radiotherapy in metastatic spinal cord compression: results of a phase III, randomized, multicenter trial. J Clin Oncol. 2005;23:3358–65. doi: 10.1200/JCO.2005.08.193. [DOI] [PubMed] [Google Scholar]
  • 5.Quinn JA, DeAngelis LM. Neurologic emergencies in the cancer patient. Semin Oncol. 2000;27:311–21. [PubMed] [Google Scholar]
  • 1.http://www.caudaequina.org/ Cauda Equina Portal
  • 2.http://www.emedicine.com/EMERG/topic85.htm E-medicine
  • 3.http://www.merck.com/mmhe/sec06/ch093/ch093c.htm Merck Manual
  • 1.Keefe DL. Cardiovascular emergencies in the cancer patient. Semin Oncol. 2000;27:244–55. [PubMed] [Google Scholar]
  • 2.Little WC, Freeman GL. Pericardial disease. Circulation. 2006;113:1622–32. doi: 10.1161/CIRCULATIONAHA.105.561514. [DOI] [PubMed] [Google Scholar]
  • 3.Martinoni A, Cipolla CM, Civelli M, et al. Intrapericardial treatment of neoplastic pericardial effusions. Herz. 2000;25:787–93. doi: 10.1007/PL00001998. [DOI] [PubMed] [Google Scholar]
  • 4.Retter AS. Pericardial disease in the oncology patient. Heart Dis. 2002;4:387–91. doi: 10.1097/00132580-200211000-00008. [DOI] [PubMed] [Google Scholar]
  • 5.Soler-Soler J, Sagrista-Sauleda J, Permanyer-Miralda G. Management of pericardial effusion. Heart. 2001;86:235–40. doi: 10.1136/heart.86.2.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Spodick DH. Acute cardiac tamponade. N Engl J Med. 2003;349:684–90. doi: 10.1056/NEJMra022643. [DOI] [PubMed] [Google Scholar]
  • 1.http://www.emedicine.com/med/topic1786.htm E-medicine
  • 2.http://www.emedicine.com/emerg/topic412.htm E-medicine
  • 3.http://www.nkm.nih.gov/medlineplus/ency/articl/000194.htm MedlinePlus
  • 1.Bajorunas DR. Clinical manifestations of cancer-related hypercalcemia. Semin Oncol. 1990;17:16–20. [PubMed] [Google Scholar]
  • 2.Flombaum CD. Metabolic emergencies in the cancer patient. Semin Oncol. 2000;27:322–34. [PubMed] [Google Scholar]
  • 3.Perry CM, Figgitt DP. Zoledronic acid. Drugs. 2004;64:1197–211. doi: 10.2165/00003495-200464110-00004. [DOI] [PubMed] [Google Scholar]
  • 4.Stewart AF. Hypercalcemia associated with cancer. N Engl J Med. 2005;352:373–9. doi: 10.1056/NEJMcp042806. [DOI] [PubMed] [Google Scholar]
  • 1.http://www.cancer.gov/cancertopics/pdq/supportivecare/
hypercalcemia/patient NCI Cancer Topics
  • 2.http://www.emedicine.com/emerg/topic 260.htm E-medicine
  • 1.Cairo MS, Bishop M. Tumor lysis syndrome: new therapeutic strategies and classification. Br J Hematol. 2004;127:3–11. doi: 10.1111/j.1365-2141.2004.05094.x. [DOI] [PubMed] [Google Scholar]
  • 2.Del Toro G, Morris E, Cairo MS. Tumor lysis syndrome: pathophysiology, definition and alternative treatment approaches. Clin Adv Hematol Oncol. 2005;3:54–61. [PubMed] [Google Scholar]
  • 3.Nicolin G. Emergencies and their management. Eur J Cancer. 2002;38:1365–77. doi: 10.1016/S0959-8049(02)00072-2. [DOI] [PubMed] [Google Scholar]
  • 1.http://www.emedicine.com/MED/topic2327.htm E-medicine
  • 2.http:www.answers.com/topic/tumor-lysis-syndrome Infoportal
  • 1.British Committee for Standards in Haematology Guidelines on the management of massive blood loss. Br J Haematol. 2006;135:634–41. doi: 10.1111/j.1365-2141.2006.06355.x. [DOI] [PubMed] [Google Scholar]
  • 2.Imbesi JJ, Kurtz RC. A multidisciplinary approach to gastrointestinal bleeding in cancer patients. J Support Oncol. 2005;3:102–10. [PubMed] [Google Scholar]
  • 3.Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med. 2007;356:2301–11. doi: 10.1056/NEJMra067742. [DOI] [PubMed] [Google Scholar]
  • 4.Pereira J, Phan T. Management of bleeding in patients with advanced cancer. Oncologist. 2004;9:561–70. doi: 10.1634/theoncologist.9-5-561. [DOI] [PubMed] [Google Scholar]
  • 5.Reimann T, Butts CA. Upper gastrointestinal bleeding as a metastatic manifestation of breast cancer: a case report and review of the literature. Can J Gastroenterol. 2001;15:67–71. doi: 10.1155/2001/898434. [DOI] [PubMed] [Google Scholar]
  • 1.http://www.cancernetwork.com/textbook/morev42.htm#Cardiovascular%20Emergencies
  • 2.http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=cmed6.section.43920
  • 1.Davenport DD. Pathophysiology of hemolytic transfusion reactions. Semin Hematol. 2005;42:165–9. doi: 10.1053/j.seminhematol.2005.04.006. [DOI] [PubMed] [Google Scholar]
  • 2.Dzik WH. New technology for transfusion safety. Br J Haematol. 2006;136:181–90. doi: 10.1111/j.1365-2141.2006.06373.x. [DOI] [PubMed] [Google Scholar]
  • 3.Pomper GJ, Wu Y, Snyder EL. Risks of transfusion-transmitted infections 2003. Curr Opin Hematol. 2003;10:412–8. doi: 10.1097/00062752-200311000-00003. [DOI] [PubMed] [Google Scholar]
  • 4.Popovsky MA, editor. Transfusion Reactions. 2. Bethesda, USA: AABB Press; 2001. [Google Scholar]
  • 5.Schroeder ML. Transfusion-associated graft-versus-host disease. Br J Haematol. 2002;117:257–87. doi: 10.1046/j.1365-2141.2002.03450.x. [DOI] [PubMed] [Google Scholar]
  • 6.Sillmann CC, Ambrusi DR, Boshkov LK. Transfusion-related acute lung injury. Blood. 2005;105:2266–73. doi: 10.1182/blood-2004-07-2929. [DOI] [PubMed] [Google Scholar]
  • 1.http://www.emedicine.com/emerg/topic063.htm E-medicine
  • 2.http://www.nlm.nih.gov/medlineplus/ency/article/001303.htm Medline Plus
  • 3.http://www.psbc.org/medical/transfusion/bcrm/section_c/default.ht Puget Sound Blood Ctr
  • 4.http://www3.mdanderson.org/~citm/ MD Anderson, Transfusion Reactions
  • 1.Davies AG, Russell WC, Thompson JP. Extravasation and tissue necrosis due to central line infusions. Anaesthesia. 2003;58:820–1. doi: 10.1046/j.1365-2044.2003.03295_26.x. [DOI] [PubMed] [Google Scholar]
  • 2.Ener RA, Meglathery SB, Styler M. Extravasation of systemic hemato-oncological therapies. Ann Oncol. 2004;15:858–62. doi: 10.1093/annonc/mdh214. [DOI] [PubMed] [Google Scholar]
  • 3.Goolsby TV, Lombardo FA. Extravasation of chemotherapeutic agents: prevention and treatment. Semin Oncol. 2006;33:139–42. doi: 10.1053/j.seminoncol.2005.11.007. [DOI] [PubMed] [Google Scholar]
  • 4.Kurul SP, Saip P, Aydin T. Totally implantable venous-access ports: local problems and extravasation injury. Lancet Oncol. 2002;3:684–92. doi: 10.1016/S1470-2045(02)00905-1. [DOI] [PubMed] [Google Scholar]
  • 5.Napoli P, Corradino B, Badalamenti G, et al. Surgical treatment of extravasation injuries. J Surg Oncol. 2005;91:264–8. doi: 10.1002/jso.20248. [DOI] [PubMed] [Google Scholar]
  • 6.Schrijvers DL. Extravasation: a dreaded complication of chemotherapy. Ann Oncol. 2003;14(suppl 3):iii26–30. doi: 10.1093/annonc/mdg744. [DOI] [PubMed] [Google Scholar]
  • 7.Schulmeister L. Managing vesicant extravasations. Oncologist. 2008;13:284–8. doi: 10.1634/theoncologist.2007-0191. [DOI] [PubMed] [Google Scholar]
  • 1.http://www.extravasation.org.uk/home.htm Natl Extravasation Info

Articles from Concise Manual of Hematology and Oncology are provided here courtesy of Nature Publishing Group

RESOURCES